ATS 2024 Final Program

Click on the session title to view the speakers

291

TUESDAY • MAY 21

Objectives At the conclusion of this session, the participant will be able to: • define the contribution of viral pathogens to the overall burden of sepsis and describe challenges in applying traditional methods of sepsis surveillance to identify viral sepsis • discuss intersection between existing sepsis phenotyping efforts and viral sepsis for understanding pathophysiology of sepsis and implications for previous and future interventional trials • describe implications of viral sepsis for current sepsis treatment protocols and potential need for policy change to address one-size-fits-all approach to sepsis Sepsis is the syndrome of life-threatening organ dysfunction caused by a dysregulated host response to infection. While all consensus definitions of sepsis have been agnostic to the type of pathogen which triggers this host response, clinicians, policymakers, and researchers have historically equated sepsis primarily with bacterial infections. The SARS-CoV-2 pandemic raised awareness that viral infections are (and always have been) important contributors to the total burden of sepsis for both adults and children, with important implications for the understanding of sepsis epidemiology, pathophysiology, and ideal treatment approaches. 2:15 Introduction 2:21 Undercounted: Best Estimates and Challenges in Measuring the Burden of Viral Sepsis 2:35 Overtreated: Reconciling Viral Sepsis with Surviving Sepsis 2:49 Undifferentiated: Causative Pathogen Type as Potential Key to Unpacking Sepsis Heterogeneity 3:03 Dysregulated: How the Immune Response Varies in Viral vs Bacterial Sepsis and What it Means for Immunomodulating Therapies 3:17 A Trialist’s Dilemma: Enroll or Exclude? 3:31 Lessons from Littles: What We Can Learn from Pediatric Sepsis, Where Viruses Have Long Ruled

studies. Undoubtedly, PPF is shaping the ILD clinical and research landscape - and yet there is limited consensus on how it should be defined, identified, or applied. In this scientific session, we propose a Pro-Con debate designed to evaluate the evolutionary state of PPF with the goal of identifying areas of consensus and controversy that should guide future investigation and application. 2:15 Progressive Pulmonary Fibrosis: Taking Stock 2:20 Pro: PPF - Is It a Meaningful Diagnosis? 2:29 Con: PPF - Is It a Meaningful Diagnosis? 2:38 Audience Discussion and Debate 2:47 Pro: Can Precision Medicine Predict PPF? Are We There Yet? 2:56 Con: Can Precision Medicine Predict PPF? Are We There Yet? 3:05 Audience Discussion and Debate 3:14 Pro: Should the PFF Designation Be Used for Future ILD Clinical Trial Design? 3:23 Con: Should the PFF Designation Be Used for Future ILD Clinical Trial Design? 3:32 Audience Discussion and Debate 3:41 Progressive Pulmonary Fibrosis: Where Do We Go From Here? This session and the International Conference are supported by an independent medical educational grant from Boehringer IngelheimPharmaceuticals, Inc. All CMEsessions have been planned and implemented in accordancewith the AccreditationCriteria of theAccreditationCouncil for ContinuingMedical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

CLINICAL • TRANSLATIONAL CRITICAL CARE TRACK

C83 WHEN SEPSIS GOES VIRAL:

RECONSIDERING SEPSIS IN THE POST-COVID ERA Assemblies on Critical Care; Clinical Problems; Pediatrics; Pulmonary Infections and Tuberculosis 2:15 p.m. - 3:45 p.m. San Diego Convention Center Room 24A-C (Upper Level) Target Audience: All who care for patients with sepsis and/or research sepsis epidemiology, outcomes, pathophysiology, and/or treatments

ATS 2024 Conference Program • San Diego, CA